
-
OPKO Health NasdaqGS:OPK OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Location: 4400 Biscayne Boulevard, Miami, FL, 33137, United States | Website: https://www.opko.com | Industry: Diagnostics & Research | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.143B
Cash
428.8M
Avg Qtr Burn
-45.62M
Short % of Float
9.07%
Insider Ownership
46.82%
Institutional Own.
31.11%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NGENLA® Somatrogon Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
Rayaldee (calcifediol ER capsules) Details Chronic kidney disease | Approved Quarterly sales | |
OPK88003 (oxyntomodulin analog) (GLP-1R/GCGR agonist) Details Type 2 diabetes | Phase 2 Update | |
MDX2201 Details Epstein-Barr virus, Vaccine | Phase 1 Data readout | |
SAR441236 Details Human immunodeficiency virus | Phase 1 Update | |
MDX2001 (Tetraspecific LASER) Details Cancer, Solid tumor/s | Phase 1 Update | |
Rayaldee Details COVID-19 | Failed Discontinued |